Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ: HALO )

57.75 +0.31 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,299,870
Open 58.00
Bid (Size) 56.25 (1)
Ask (Size) 58.00 (1)
Prev. Close 57.44
Today's Range 57.32 - 58.74
52wk Range 37.73 - 65.53
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill

Performance

YTD
+20.29%
+20.29%
1 Month
+3.81%
+3.81%
3 Month
+20.84%
+20.84%
6 Month
-7.09%
-7.09%
1 Year
+42.38%
+42.38%

More News

Read More
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
Via Chartmill
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via Chartmill
Analyst Expectations For Halozyme Therapeutics's Future
Via Benzinga
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Earnings Scheduled For February 18, 2025
Via Benzinga
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
Via Benzinga
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Via Benzinga
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.